Evidence map›Paper›PMID 40642799›Full record

ArticleJournal of biosciences2025

Postbiotic potential of SCFAs on metaflammation and gut microbiota alteration in diabetes.

Dipeeka K Mandaliya, Sweta Patel, Sriram Seshadri

Abstract read
PubMed
In one paragraph

Article in Journal of biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dipeeka K MandaliyaInstitute of Science, Nirma University, Ahmedabad, Gujarat, India.
Sweta Patel
Sriram Seshadri

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gut microbiota regulate host metabolism via its fermentation products, mainly short-chain fatty acids (SCFAs), i.e., acetate, propionate, and butyrate. Although butyrate is studied for its anti-inflammatory, anti-obesity, and anti-diabetic effects, propionate alone and in combination with acetate or butyrate is not well reported. In this study, we have shown the combinatorial effect of propionate with acetate or butyrate in the regulation of diabetes characteristics, liver metabolism, and inflammation via SCFA receptors and gut microbiota modulation. Diabetes was induced by high-fat diet administration for 4 months and was followed by oral administration of SCFAs for 1 month. Although propionate and butyrate alone showed reduced diabetic characteristics, a combination of propionate with acetate or butyrate more significantly regulated insulin downstream pathway molecules, i.e., liver X receptor (LXR), sterol regulatory element binding protein 1c (SREBP1c), glucose transporter type 4 (GLUT4), and peroxisome-proliferator-activated receptor alpha (PPARα), and enhanced the expression of SCFA receptors, i.e., G-protein-coupled receptor 41 (GPR41), GPR43, and GPR109 in the liver. They increased microbial richness and evenness along with the restoration of probiotic bacterial strains, healthy bacteria, as well as butyrate producers, mainly,

Indexed as

Diabetes Mellitus, ExperimentalFatty Acids, VolatileGastrointestinal MicrobiomeInflammationAcetatesAnimalsButyratesDiet, High-FatLiverLiver X ReceptorsMaleMiceMice, Inbred C57BLPPAR alphaProbioticsPropionatesAcetatesButyratesFatty Acids, VolatileLiver X ReceptorsPPAR alphaPropionatesReceptors, G-Protein-CoupledSterol Regulatory Element Binding Protein 1

Identifiers

PMID40642799

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.